Review, historical context, and clarifications of the NINDS rt-PA stroke trials exclusion criteria: Part 1: rapidly improving stroke symptoms.

ABSTRACT:

Background and purpose

Since Food and Drug Administration approval of intravenous tissue-type plasminogen activator (tPA) for treatment of acute ischemic stroke in 1996, it has become clear that several criteria used for exclusion from therapy were not based on actual data or operationally defined for use in clinical practice. All eligibility criteria from the National Institute of Neurological Disorders and Stroke (NINDS) recombinant tPA Stroke Study were adopted within the alteplase package insert as contraindications/warnings. Many clinicians have expressed the need for clarification and better definition of these treatment criteria.

Methods

A group of investigators who also practice as stroke physicians convened a collaborative endeavor to work toward developing more cli

SUBMITTER: Re-examining Acute Eligibility for Thrombolysis (TREAT) Task Force: 

PROVIDER: S-EPMC3789593 | biostudies-literature | 2013 Sep

REPOSITORIES: biostudies-literature